Your browser doesn't support javascript.
loading
Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring Systems.
Eichenlaub, Manuel; Pleus, Stefan; Rothenbühler, Martina; Bailey, Timothy S; Bally, Lia; Brazg, Ronald; Bruttomesso, Daniela; Diem, Peter; Eriksson Boija, Elisabet; Fokkert, Marion; Haug, Cornelia; Hinzmann, Rolf; Jendle, Johan; Klonoff, David C; Mader, Julia K; Makris, Konstantinos; Moser, Othmar; Nichols, James H; Nørgaard, Kirsten; Pemberton, John; Selvin, Elizabeth; Spanou, Loukia; Thomas, Andreas; Tran, Nam K; Witthauer, Lilian; Slingerland, Robbert J; Freckmann, Guido.
Afiliação
  • Eichenlaub M; Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.
  • Pleus S; Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.
  • Rothenbühler M; IFCC Scientific Division, Working Group on Continuous Glucose Monitoring.
  • Bailey TS; Diabetes Center Berne, Bern, Switzerland.
  • Bally L; AMCR Institute, Escondido, California, USA.
  • Brazg R; Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital Bern, Bern University Hospital and University of Bern, Bern, Switzerland.
  • Bruttomesso D; Rainier Clinical Research Center, Renton, Washington, USA.
  • Diem P; Division of Metabolic Disease, Department of Medicine, University of Padua, Padua, Italy.
  • Eriksson Boija E; IFCC Scientific Division, Working Group on Continuous Glucose Monitoring.
  • Fokkert M; Endokrinologie Diabetologie Bern, Bern, Switzerland.
  • Haug C; IFCC Scientific Division, Working Group on Continuous Glucose Monitoring.
  • Hinzmann R; Equalis AB, Uppsala, Sweden.
  • Jendle J; IFCC Scientific Division, Working Group on Continuous Glucose Monitoring.
  • Klonoff DC; Department of Clinical Chemistry, Isala Clinics, Zwolle, The Netherlands.
  • Mader JK; Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.
  • Makris K; IFCC Scientific Division, Working Group on Continuous Glucose Monitoring.
  • Moser O; Roche Diabetes Care GmbH, Mannheim, Germany.
  • Nichols JH; IFCC Scientific Division, Working Group on Continuous Glucose Monitoring.
  • Nørgaard K; School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Pemberton J; IFCC Scientific Division, Working Group on Continuous Glucose Monitoring.
  • Selvin E; Diabetes Research Institute of Mills-Peninsula Medical Center, San Mateo, California, USA.
  • Spanou L; Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
  • Thomas A; IFCC Scientific Division, Working Group on Continuous Glucose Monitoring.
  • Tran NK; Clinical Biochemistry Department, KAT General Hospital, Athens, Greece.
  • Witthauer L; Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
  • Slingerland RJ; Department of Exercise Physiology and Metabolism, University of Bayreuth, Bayreuth, Germany.
  • Freckmann G; IFCC Scientific Division, Working Group on Continuous Glucose Monitoring.
Diabetes Technol Ther ; 26(4): 263-275, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38194227
ABSTRACT
Comparing the performance of different continuous glucose monitoring (CGM) systems is challenging due to the lack of comprehensive guidelines for clinical study design. In particular, the absence of concise requirements for the distribution of comparator (reference) blood glucose (BG) concentrations and their rate of change (RoC) that are used to evaluate CGM performance, impairs comparability. For this article, several experts in the field of CGM performance testing have collaborated to propose characteristics of the distribution of comparator measurements that should be collected during CGM performance testing. Specifically, it is proposed that at least 7.5% of comparator BG concentrations are <70 mg/dL (3.9 mmol/L) and >300 mg/dL (16.7 mmol/L), respectively, and that at least 7.5% of BG-RoC combinations indicate fast BG changes with impending hypo- or hyperglycemia, respectively. These proposed characteristics of the comparator data can facilitate the harmonization of testing conditions across different studies and CGM systems and ensure that the most relevant scenarios representing real-life situations are established during performance testing. In addition, a study protocol and testing procedure for the manipulation of glucose levels are suggested that enable the collection of comparator data with these characteristics. This work is an important step toward establishing a future standard for the performance evaluation of CGM systems.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Hiperglicemia Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Hiperglicemia Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha
...